
Skin cancer research
Success: Treatment outcomes in skin cancer

Dr Jessica Duarte
Dr Jessica Duarte is a Postdoctoral Research Fellow at the Olivia Newton-John Cancer Research Institute.
In 2021, Dr Jessica Duarte was generously funded by the Denton Family Trust through Cancer Australia Priority-driven Collaborative Cancer Research Scheme.
Through her first Cure Cancer grant in 2019, Dr Jessica was able to develop a non-invasive technology that measures a patient’s response to treatments aimed at boosting immunity. Although she focussed her work on patients undergoing immunotherapy for melanoma, the application of this research has potential for immunotherapy for all cancer types, including ones that are rare and have a few treatment options.
It is especially significant for patients with rare cancer types, as rare cancers have low incidence, low survival rates, and are often excluded from clinical trials and biomarker studies. Through her project, Dr Jessica is measuring the cancer-specific antibody repertoire of rare cancer patients who are undergoing combination immunotherapy. Her current analyses are already showing an improved prediction for treatment outcomes, and she aims to complete data validation in 2022.
Together, we can cure cancer.

Lunch & Learn series
Find out about the latest developments in cancer research first hand from our researchers and the impact of your support.
We take on every cancer
Cure Cancer funds ground breaking research across every cancer, no matter the size or rarity.
We aim to maximise our impact, save millions of lives, and leaves no one behind.

Our research grant program
We are dedicated to funding new innovative cancer research projects, giving talented emerging cancer researchers the opportunity to pursue their innovative ideas across diverse areas of cancer research.
Through our Research Grants Program, we commit to back new ideas from the most brilliant minds in cancer research.
Let's stay in touch
To receive updates on our work, campaigns and our impact in cancer research, subscribe to our newsletter.